Sharp Therapeutics Corp. (SHRXF)
| Market Cap | 21.28M |
| Revenue (ttm) | n/a |
| Net Income | -6.17M |
| EPS | -0.21 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 100 |
| Open | 1.600 |
| Previous Close | n/a |
| Day's Range | 1.600 - 1.600 |
| 52-Week Range | 0.304 - 3.460 |
| Beta | -1.58 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 26, 2026 |
About Sharp Therapeutics
Sharp Therapeutics Corp., a preclinical-stage drug discovery company, develops therapeutics for genetic diseases. The company engages in the development of the CoreX, a suite of biology technologies that allows the creation of sensitive assays mimicking the genetic disease state, enabling discovery of compounds that correct the mutational defect; AlloChem, a compound library which binds proteins allosterically; and Mine, a custom-built, cloud-distributed analytics platform that captures data for AlloChem compounds in CoreX assays. Sharp Therape... [Read more]
Financial Performance
Financial StatementsNews
Sharp Therapeutics Presents New Preclinical Data Supporting Novel Small-Molecule Therapeutic Approach for Niemann-Pick Disease Type C
Novel lead small molecules demonstrate substantial reduction of cholesterol accumulation in NPC patient-derived fibroblasts, with additional data supporting lysosomal health and cellular signaling
Sharp Therapeutics Corp. Announces Fourth Quarter 2025 Results, Closing of Convertible Note Offering and Adoption of Semi-Annual Reporting
Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - April 17, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") announces the release of its annual a...
Sharp Therapeutics Updates on '901 for Gaucher and GBA1 Parkinson's and Platform Programs
Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - April 10, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") announces that following longer-term ...
Sharp Therapeutics Announces Closing of Fourth Tranche of Unsecured Convertible Note Offering
Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - April 10, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce that it has cl...
Sharp Therapeutics Announces Closing of Third Tranche of Unsecured Convertible Note Offering
Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - April 2, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce that it has clo...
Sharp Therapeutics Announces Closing of Second Tranche of Unsecured Convertible Note Offering
Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - March 13, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce that it has cl...
Sharp Therapeutics Announces Closing of First Tranche of Unsecured Convertible Note Offering
Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - February 27, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce that it has...
Sharp Therapeutics Announces Private Placement of up to US$3.0 Million in Unsecured Convertible Notes
Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - February 2, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce the terms of...
Sharp Therapeutics Appoints Co-Founder Of National Gaucher Foundation And Clinical Researcher Robin Ely, M.D., To Advisory Board
PITTSBURGH and TORONTO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Sharp Therapeutics Corp. ("Sharp" or the "Company") (TSX-V: SHRX) (OTCQB: SHRXF), a biotechnology company developing small-molecule therapeuti...
Sharp Therapeutics Provides Update on Non-Brokered Private Placement and Grant of Options
Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - December 19, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company"), is pleased to announce that the n...
Sharp Therapeutics Corp. Reports Third Quarter 2025 Results and Development Update
Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - November 26, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company"), announces the release of its cond...
Sharp Therapeutics Arranges Non-Brokered Private Placement
Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - October 14, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company"), is pleased to announce that it is ...
Sharp Therapeutics to Present Pipeline and Program Updates at World Orphan Drug Congress 2025
PITTSBURGH, Pa. and TORONTO, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Sharp Therapeutics Corp. ("Sharp" or the "Company") (TSX-V: SHRX) (OTCQB: SHRXF), a biotechnology company developing small-molecule thera...
Sharp Therapeutics Corp. Reports Second Quarter 2025 Results and Expands Market Presence with Listing On OTCQB
Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - August 29, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") announces the release of its condens...